Table 1.
Changes in CRABP1 detected in human patients.
| Cancer Type | CRABP1 Status | Reference |
|---|---|---|
| Breast Cancer | Over-Expression | [61] |
| Prostate Cancer | Over-Expression | [60] |
| Mesenchymal & Neuroendocrine Tumors | Over-Expression | [59] |
| Head and Neck Squamous Cell Carcinoma (HNSCC) | Over-Expression | [58] |
| Colorectal Cancer | Silenced (Promoter Hypermethylation) |
[57] |
| Thyroid Cancer | Silenced (Promoter Hypermethylation) |
[56] |
| Reduced Expression | [54] | |
| Ovarian Cancer | Silenced (Promoter Hypermethylation) |
[53] |
| Reduced Expression | [52] | |
| Esophageal Squamous-Cell Carcinoma (ESCC) | Silenced (Promoter Hypermethylation) |
[51] |
| Renal Cell Carcinoma | Reduced Expression | [50] |
| Acute myeloid leukemia (AML) | Silenced (Promoter Hypermethylation) |
[49] |
| Neurodegenerative Diseases | CRABP1 Status | Reference |
| Amyotrophic Lateral Sclerosis (ALS) | Reduced Expression | [88] |
| Spinal Muscular Atrophy (SMA) | Reduced Expression | [89] |
| Late-Stage Age-Related Macular Degeneration (AMD) | Reduced Expression | [90] |
| Immune Disorders | CRABP1 Status | Reference |
| Multiple Sclerosis | Reduced Expression | [91] |
| Cutaneous Lupus Erythematosus (CLE) | Reduced Expression | [92] # E-MTAB-5542 |
| Psoriasis | Reduced Expression | [93] # E-GEOD-52471 |
| Vitiligo | Reduced Expression | [94] # E-GEOD-65127 |
| Inflammatory Bowel Disease (IBD) | Silenced (Promoter Hypermethylation) |
[95] |
| Other Diseases | CRABP1 Status | Reference |
| Moyamoya Disease (MMD) | Increased Protein Level | [96] |
| Diabetic Neuropathy | Increased Expression | [97] |
| HIV Therapy-Associated Lipodystrophy and Metabolic Syndrome | Inhibited Function | [98] |
# EMBL-EBI Expression Atlas Data Repository Accession ID.